North America White Biotech Market Report

North America White Biotech Market Size

The North America white biotech market size was valued at USD 109.62 billion in 2025 and is predicted to reach USD 217.13 billion by 2034 from USD 118.27 billion in 2026, growing at a CAGR of 7.89%.

White biotechnology is transforming a field that has evolved energy production and benefits various industries through its products. In the previous years, white biotechnology has been crucial in products like laundry detergents. The products are also used to produce penicillin, a variety of animal alternatives to insulin, and to produce many vaccines and medications.

Market Drivers and Restraints:

Industrial applications of biotechnology hold many promises of sustainable development. The increasing acceptance of novel technologies like bioprocess modeling and metabolic modeling are driving demand in this market. Also, increasing awareness of the environmental and functional benefits of biofuel use in developed and developing economies is expected to be the main driver of growth in the white biotech market. Besides, factors such as the growing demand for bioplastics, favorable government policies, constant research and innovation to develop efficient and high-quality APIs and the reduction of costs in the production process are greatly increasing the growth of the industry. Regulators continually strive to improve the predictability and effectiveness of future biotech products through their continued efforts. The governments of the United States, China, Brazil, Southeast Asia, India, and European countries have implemented several favorable tax reduction policies and tax incentives to promote applications. of white biotechnology. For example, the Executive Office of the President (EOP) presented a memorandum on July 2, 2015, directing major agencies that regulate biotech products to update the coordinated framework for biotech regulation. The agency is constantly involved in developing a long-term strategy to ensure that the federal biotechnology regulatory system is ready to strengthen the future landscape for biotech products.

Market Segmentation

The North America White Biotech Market is segmented by type and distribution channel. By type, the market is divided into Cakes and Pastries, Morning Goods, Biscuits and Cookies, Breakfast Cereals, and Bread. By distribution channel, the market is separate as Online Retail, Convenience Stores, Specialist Stores, Supermarket/Hypermarket, and others.

Impact of COVID-19 on North America White Biotech Market

The onset of the coronavirus pandemic coincided with the peak of the harvest season. As markets are closed, there is a threat to harvest on more than 100 lakh hectares in the country. Even between different segments, the impact varies considerably by region and between producers and agricultural workers. This impact will have repercussions throughout the economy and will last more than a few months. Despite all the measures and in view of the persistent restrictions on the movement of people and the movement of vehicles, concerns were expressed regarding the negative consequences of the COVID19 pandemic on the agricultural economy. For plant production, most of the planting process will be almost unaffected by summer. Therefore, there would be no impact as such on seed availability at this time. But if the same scenario continues until the end of the year, then seed availability can certainly be a problem. Due to disruption of world trade, farmers face a shortage of agricultural inputs such as fertilizers and pesticides. In a shorter period of time, there is little expected shortage. In the long term, delivery of fertilizers through international markets could become a problem, as some production plants in China have been closed.

REPORT COVERAGE

Regional Analysis

The North America White Biotech market has been categorized by region into the United States, Canada, Mexico and rest of North America. North America is currently the largest regional market for this technology, accounting for over 35% of total market revenues in 2015 owing to the considerable government funding for R&D in the field and the growing demand for green products and products. Consumer chemicals are the main factors that have strengthened North America's position in the world market.

Leading Company

Cargill Inc. had the largest share of the North America White Biotech Market in terms of sales revenue in 2019.

Key Players

Key players in the North America White Biotech Market include Novozymes, Cargill Inc., BASF SE, DuPont, and Archer Daniels Midland Company.

Recent Developments 

• In May 2014, Kaneka signed a collaboration agreement with Terumo BCT Inc. to request clinical trials in the United States for its new LDL absorption system. Additionally, the Spectra Optia system can be found in hospitals across the United States, so, unlike the current situation, it will not be necessary to bring specialized devices or train hospital staff in the use of the device.
• Ra Pharmaceuticals (RARX) Shares doubled after Belgian Biotech Company UCB announced it was buying the biotech company for $ 2.1 billion in cash.
• Gilead has announced plans to acquire nearly half of the Pionyr anticancer biotechnology, with an exclusive option to acquire the rest of the company as the large pharmaceutical company continues to expand in oncology.
• Servier has signed a definitive agreement to acquire Symphogen A/S antibody discovery biotechnology. This acquisition, the result of a process that has been ongoing for several months, will strengthen Servier's antibody capabilities and ensure that the platform for development Symphogen early and antibody discovery are fully utilized.
• French pharmacist Sanofi agreed to buy Belgian biotech company Ablynx for € 3.9 billion ($ 4.8 billion), beating Novo Nordisk and achieving its second big deal after buying Bioverativ.
• TWB and Hamilton made a partnership deal for a period of 18 months to implement innovative bioprocessing. This platform, with 24 integrated mini-reactors (50 ml), will greatly accelerate the process of developing industrial bioprocess solutions.
• White Biotech BRAIN AG has purchased specific gene-based industrial biotechnology assets from MerLion Pharmaceuticals GmbH.
• Pfizer paid $ 3.6 billion for King Pharmaceuticals, a far cry from its 2009 acquisition of Wyeth, on which it spent $ 68 billion. Pfizer, like Novartis, is no stranger to major mergers; in 2000, he gave Warner Lambert $ 89 billion.